Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Vaxart appoints W. Mark Watson to board of directors » 08:12
08/08/22
08/08
08:12
08/08/22
08:12
VXRT

Vaxart

$4.10 /

+0.195 (+4.99%)

Vaxart announced that W.…

Vaxart announced that W. Mark Watson was appointed to the Company's Board of Directors, effective August 4, 2022. Watson will become Chair of the Company's Audit Committee, effective October 1. Robert A. Yedid, a member of the Board and the Audit Committee, was appointed Interim Chairperson of the Audit Committee, to serve until Mr. Watson becomes Chair. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu and its predecessor, most recently as Central Florida Marketplace Leader.

ShowHide Related Items >><<
VXRT Vaxart
$4.10 /

+0.195 (+4.99%)

VXRT Vaxart
$4.10 /

+0.195 (+4.99%)

05/19/22 B. Riley
Vaxart price target lowered to $6 from $7 at B. Riley
02/28/22 Piper Sandler
Piper Sandler 'impressed' by Vaxart's progress in COVID, norovirus programs
01/13/22 Piper Sandler
Vaxart COVID booster on track for first half of the year, says Piper Sandler
12/29/21 Jefferies
Vaxart assumed with a Buy at Jefferies
VXRT Vaxart
$4.10 /

+0.195 (+4.99%)

VXRT Vaxart
$4.10 /

+0.195 (+4.99%)

Over a week ago
Hot Stocks
Vaxart stockholders approve proxy proposals 2, 3, and 4 » 08:06
08/05/22
08/05
08:06
08/05/22
08:06
VXRT

Vaxart

$3.91 /

+0.105 (+2.76%)

Vaxart announced that at…

Vaxart announced that at its reconvened Annual Meeting of Stockholders on August 4, its stockholders had voted to approve Proposals 2, 3 and 4. Proposal 2 is an amendment to the Company's Restated Certificate of Incorporation to increase the authorized number of shares of its common stock to 250 million shares. Proposal 3 involved an Amendment and Restatement of the 2019 Equity Incentive Plan. Proposal 4 sought stockholder approval for the 2022 Employee Stock Purchase Plan. Proposals 3 and 4 were contingent on the passage of Proposal 2. While Proposal 2 had previously received strong support from voting stockholders at the initial annual meeting in June, the votes in support of this proposal had not surpassed the 50% of outstanding shares required for it to pass. In the tally Vaxart announced yesterday, Proposal 2 was supported by 82% of the voting shares, with the votes in favor totaling 1.5 million more than the 50% of outstanding shares required for it to pass. "Since our last adjournment, Proposal 2 received 3.4 million additional votes in favor from our investors around the world," said Andrei Floroiu, Chief Executive Officer. "After speaking to many of our investors over the past two months, we have been energized by how passionately they believe in what Vaxart is trying to achieve. I want to thank our stockholders for their support and passion, as well as their strong vote of confidence in our goals and Vaxart's team." With the passage of Proposals 2, 3 and 4, Vaxart's stockholders have approved all six of the 2022 Proposals described in Vaxart's 2022

ShowHide Related Items >><<
VXRT Vaxart
$3.91 /

+0.105 (+2.76%)

VXRT Vaxart
$3.91 /

+0.105 (+2.76%)

05/19/22 B. Riley
Vaxart price target lowered to $6 from $7 at B. Riley
02/28/22 Piper Sandler
Piper Sandler 'impressed' by Vaxart's progress in COVID, norovirus programs
01/13/22 Piper Sandler
Vaxart COVID booster on track for first half of the year, says Piper Sandler
12/29/21 Jefferies
Vaxart assumed with a Buy at Jefferies
VXRT Vaxart
$3.91 /

+0.105 (+2.76%)

VXRT Vaxart
$3.91 /

+0.105 (+2.76%)

Hot Stocks
Vaxart provides update on proxy voting » 08:08
07/27/22
07/27
08:08
07/27/22
08:08
VXRT

Vaxart

$3.75 /

-0.01 (-0.27%)

Vaxart urged its…

Vaxart urged its stockholders of record on April 11, 2022, to vote on its proxy if they have not yet done so and encouraged them to vote yes on all Proxy Proposals, including Proxy Proposal #2. Proposal #2 is an amendment to the Company's Restated Certificate of Incorporation to increase the authorized number of shares of its common stock to 250 million shares. "Proposal #2 is important for shareholders and for the company, because it would enable us to continue to work to unlock and create value by investing in the business so that we can progress our programs," said Andrei Floroiu, Vaxart Chief Executive Officer. "It would also allow us to maintain a strong balance sheet and remain in a strong competitive position, and it would enable us to continue to attract and retain key talent. We strongly urge shareholders to vote before the August 3, 2022, deadline. The vast majority of the shares voted, over 80%, are in favor of Proposal #2, including 8.3 million more shares in support of Proposal #2 since our Investor Q&A webcast on June 22nd. We thank those shareholders for their vote," said Mr. Floroiu. "Currently 49.1% of Vaxart's outstanding shares have voted in favor of Proposal #2, meaning that for this proposal to pass it needs an additional 0.9% of outstanding shares in favor."

ShowHide Related Items >><<
VXRT Vaxart
$3.75 /

-0.01 (-0.27%)

VXRT Vaxart
$3.75 /

-0.01 (-0.27%)

05/19/22 B. Riley
Vaxart price target lowered to $6 from $7 at B. Riley
02/28/22 Piper Sandler
Piper Sandler 'impressed' by Vaxart's progress in COVID, norovirus programs
01/13/22 Piper Sandler
Vaxart COVID booster on track for first half of the year, says Piper Sandler
12/29/21 Jefferies
Vaxart assumed with a Buy at Jefferies
VXRT Vaxart
$3.75 /

-0.01 (-0.27%)

VXRT Vaxart
$3.75 /

-0.01 (-0.27%)

On The Fly
What You Missed On Wall Street On Wednesday » 16:36
07/20/22
07/20
16:36
07/20/22
16:36
LVS

Las Vegas Sands

$37.08 /

+1.54 (+4.33%)

, MGM

MGM Resorts

$31.30 /

+0.83 (+2.72%)

, WYNN

Wynn Resorts

$61.93 /

+2.35 (+3.94%)

, MLCO

Melco Resorts & Entertainment

$5.73 /

+0.44 (+8.32%)

, BA

Boeing

$158.36 /

+2.26 (+1.45%)

, AAPL

Apple

$153.05 /

+2.13 (+1.41%)

, NFLX

Netflix

$216.46 /

+14.73 (+7.30%)

, ABT

Abbott

$108.18 /

-1.34 (-1.22%)

, BKR

Baker Hughes

$25.88 /

-2.32 (-8.23%)

, BIIB

Biogen

$207.57 /

-12.745 (-5.78%)

, MRK

Merck

$89.64 /

-2.645 (-2.87%)

, ATRA

Atara Biotherapeutics

$3.72 /

+0.07 (+1.92%)

, ANET

Arista Networks

$104.93 /

+0.135 (+0.13%)

, JNPR

Juniper

$28.54 /

-0.66 (-2.26%)

, BABA

Alibaba

$103.97 /

-0.775 (-0.74%)

, PYPL

PayPal

$80.26 /

+2.46 (+3.16%)

, RYTM

Rhythm Pharmaceuticals

$13.21 /

+2.63 (+24.86%)

, DDOG

Datadog

$100.84 /

+7.74 (+8.31%)

, VXRT

Vaxart

$4.24 /

+0.3 (+7.62%)

, RVMD

Revolution Medicines

$23.47 /

-1.145 (-4.65%)

, VALE

Vale

$12.43 /

-0.275 (-2.17%)

, BBWI

Bath & Body Works

$31.10 /

+0.985 (+3.27%)

, NDAQ

Nasdaq

$169.06 /

+9.67 (+6.07%)

, CPRI

Capri Holdings

$48.18 /

+1.9 (+4.11%)

, BMI

Badger Meter

$87.24 /

+4.96 (+6.03%)

, NTRS

Northern Trust

$97.21 /

-3.97 (-3.92%)

, NEWR

New Relic

$61.60 /

+9.215 (+17.59%)

, F

Ford

$12.73 /

+0.14 (+1.11%)

Get caught up quickly on…

ShowHide Related Items >><<
WYNN Wynn Resorts
$61.93 /

+2.35 (+3.94%)

VXRT Vaxart
$4.24 /

+0.3 (+7.62%)

VALE Vale
$12.43 /

-0.275 (-2.17%)

RYTM Rhythm Pharmaceuticals
$13.21 /

+2.63 (+24.86%)

RVMD Revolution Medicines
$23.47 /

-1.145 (-4.65%)

PYPL PayPal
$80.26 /

+2.46 (+3.16%)

NTRS Northern Trust
$97.21 /

-3.97 (-3.92%)

NFLX Netflix
$216.46 /

+14.73 (+7.30%)

NEWR New Relic
$61.60 /

+9.215 (+17.59%)

NDAQ Nasdaq
$169.06 /

+9.67 (+6.07%)

MRK Merck
$89.64 /

-2.645 (-2.87%)

MLCO Melco Resorts & Entertainment
$5.73 /

+0.44 (+8.32%)

MGM MGM Resorts
$31.30 /

+0.83 (+2.72%)

LVS Las Vegas Sands
$37.08 /

+1.54 (+4.33%)

JNPR Juniper
$28.54 /

-0.66 (-2.26%)

F Ford
$12.73 /

+0.14 (+1.11%)

DDOG Datadog
$100.84 /

+7.74 (+8.31%)

CPRI Capri Holdings
$48.18 /

+1.9 (+4.11%)

BMI Badger Meter
$87.24 /

+4.96 (+6.03%)

BKR Baker Hughes
$25.88 /

-2.32 (-8.23%)

BIIB Biogen
$207.57 /

-12.745 (-5.78%)

BBWI Bath & Body Works
$31.10 /

+0.985 (+3.27%)

BABA Alibaba
$103.97 /

-0.775 (-0.74%)

BA Boeing
$158.36 /

+2.26 (+1.45%)

ATRA Atara Biotherapeutics
$3.72 /

+0.07 (+1.92%)

ABT Abbott
$108.18 /

-1.34 (-1.22%)

AAPL Apple
$153.05 /

+2.13 (+1.41%)

LVS Las Vegas Sands
$37.08 /

+1.54 (+4.33%)

07/21/22 Stifel
Las Vegas Sands price target raised to $50 from $46 at Stifel
07/21/22 Barclays
Las Vegas Sands price target raised to $43 from $39 at Barclays
07/21/22 Citi
Las Vegas Sands price target raised to $58 from $56 at Citi
07/21/22 Wells Fargo
Las Vegas Sands upgraded to Overweight from Equal Weight at Wells Fargo
MGM MGM Resorts
$31.30 /

+0.83 (+2.72%)

07/20/22 Truist
MGM Resorts price target lowered to $35 from $48 at Truist
07/05/22 Citi
MGM Resorts price target lowered to $56 from $59 at Citi
06/28/22 JMP Securities
MGM Resorts initiated with an Outperform at JMP Securities
05/20/22 Deutsche Bank
MGM Resorts price target lowered to $48 from $52 at Deutsche Bank
WYNN Wynn Resorts
$61.93 /

+2.35 (+3.94%)

07/05/22 Citi
Wynn Resorts price target lowered to $87.50 from $92 at Citi
06/29/22 Barclays
Barclays initiates gaming sector, says Caesars best positioned
06/28/22 Barclays
Wynn Resorts initiated with an Equal Weight at Barclays
05/11/22 Deutsche Bank
Wynn Resorts price target lowered to $92 from $123 at Deutsche Bank
MLCO Melco Resorts & Entertainment
$5.73 /

+0.44 (+8.32%)

07/05/22 Citi
Melco Resorts price target lowered to $11 from $12.50 at Citi
05/09/22 CICC
Melco Resorts downgraded to Market Perform from Outperform at CICC
05/06/22 CLSA
Melco Resorts & Entertainment upgraded to Buy from Outperform at CLSA
04/12/22 Citi
Citi opens '30-day positive Catalyst Watches' on Melco, Galaxy
BA Boeing
$158.36 /

+2.26 (+1.45%)

07/18/22 Cowen
Cowen believes Aerospace and Defense quarterly results to be mixed
07/15/22 Benchmark
Boeing price target lowered to $200 from $250 at Benchmark
07/14/22 RBC Capital
Boeing price target lowered to $200 from $220 at RBC Capital
07/13/22 JPMorgan
Boeing price target lowered to $188 from $190 at JPMorgan
AAPL Apple
$153.05 /

+2.13 (+1.41%)

07/21/22 Morgan Stanley
Subscription shift could add $1T to Apple market cap, says Morgan Stanley
07/20/22 JPMorgan
China iPhone shipments better than seasonal in June, says JPMorgan
07/20/22 Morgan Stanley
Apple price target trimmed to $180 at Morgan Stanley ahead of Q3 report
07/20/22 Wells Fargo
Apple price target lowered to $185 from $205 at Wells Fargo
NFLX Netflix
$216.46 /

+14.73 (+7.30%)

07/20/22 Oppenheimer
Netflix subscriber beat unlikely to alleviate concerns, says Oppenheimer
07/20/22 Evercore ISI
Evercore says market will need to see progress from Netflix for premium multiple
07/20/22 Morgan Stanley
Netflix price target raised to $230 from $220 at Morgan Stanley
07/20/22 Wedbush
Wedbush remains bullish on Netflix following quarterly results
ABT Abbott
$108.18 /

-1.34 (-1.22%)

07/21/22 RBC Capital
Abbott price target lowered to $132 from $143 at RBC Capital
07/21/22 Citi
Abbott price target lowered to $123 from $125 at Citi
07/18/22 BTIG
Abbott price target lowered to $126 from $130 at BTIG
07/18/22 Stifel
Abbott price target lowered to $126 from $136 at Stifel
BKR Baker Hughes
$25.88 /

-2.32 (-8.23%)

07/21/22 Stephens
Baker Hughes price target lowered to $32 from $40 at Stephens
07/21/22 Barclays
Baker Hughes price target lowered to $44 from $46 at Barclays
07/13/22 Morgan Stanley
Baker Hughes price target lowered to $35 from $40 at Morgan Stanley
07/13/22 Barclays
Baker Hughes price target lowered to $46 from $47 at Barclays
BIIB Biogen
$207.57 /

-12.745 (-5.78%)

07/21/22 Barclays
Biogen price target lowered to $200 from $210 at Barclays
07/20/22 RBC Capital
Biogen price target lowered to $259 from $264 at RBC Capital
07/20/22 Piper Sandler
Biogen Q2 'surprisingly strong,' but 'rough waters' ahead, says Piper
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
MRK Merck
$89.64 /

-2.645 (-2.87%)

07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
07/12/22 H.C. Wainwright
H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
07/08/22 Morgan Stanley
Merck price target raised to $88 from $87 at Morgan Stanley
07/07/22 Daiwa
Merck upgraded to Outperform from Neutral at Daiwa (yesterday)
ATRA Atara Biotherapeutics
$3.72 /

+0.07 (+1.92%)

07/20/22 Citi
Atara Biotherapeutics downgraded to Sell from Neutral at Citi
07/13/22 Canaccord
Atara Biotherapeutics price target lowered to $50 from $67 at Canaccord
07/13/22 Stifel
Stifel downgrades Atara Biotherapeutics to Hold following ATA188 analysis
07/13/22 Stifel
Atara Biotherapeutics downgraded to Hold from Buy at Stifel
ANET Arista Networks
$104.93 /

+0.135 (+0.13%)

07/20/22 BofA
Arista double downgraded to Underperform at BofA on upcoming deterioration
07/20/22 BofA
Arista Networks downgraded to Underperform from Buy at BofA
07/19/22 Needham
Needham upgrades Arista Networks to Buy, sees the company as insulated
07/19/22 Needham
Arista Networks upgraded to Buy from Hold at Needham
JNPR Juniper
$28.54 /

-0.66 (-2.26%)

07/20/22 BofA
Juniper double downgraded to Underperform at BofA on upcoming deterioration
07/20/22 BofA
Juniper downgraded to Underperform from Buy at BofA
07/14/22 JPMorgan
Juniper upgraded to Overweight from Neutral at JPMorgan
07/13/22 Evercore ISI
Juniper added to 'Tactical Outperform' list at Evercore ISI
BABA Alibaba
$103.97 /

-0.775 (-0.74%)

07/19/22 Bernstein
Alibaba upgraded to Outperform from Market Perform at Bernstein
07/11/22 Goldman Sachs
Pinduoduo grocery focus to drive sustained growth, says Goldman Sachs
07/11/22 Goldman Sachs
Alibaba price target raised to $167 from $163 at Goldman Sachs
07/06/22 Benchmark
Alibaba price target raised to $205 from $200 at Benchmark
PYPL PayPal
$80.26 /

+2.46 (+3.16%)

07/20/22 Wolfe Research
PayPal downgraded to Peer Perform from Outperform at Wolfe Research
07/20/22 Wells Fargo
PayPal price target lowered to $97 from $115 at Wells Fargo
07/20/22 JPMorgan
PayPal price target lowered to $112 from $127 at JPMorgan
07/15/22 RBC Capital
PayPal price target lowered to $92 from $110 at RBC Capital
RYTM Rhythm Pharmaceuticals
$13.21 /

+2.63 (+24.86%)

07/20/22 Stifel
Rhythm Pharmaceuticals price target raised to $37 from $25 at Stifel
07/13/22 Ladenburg
Rhythm Pharmaceuticals price target raised to $23 from $15 at Ladenburg
07/12/22 Goldman Sachs
Rhythm Pharmaceuticals price target raised to $6 from $4 at Goldman Sachs
06/17/22 Needham
Rhythm Pharmaceuticals price target lowered to $25 from $40 at Needham
DDOG Datadog
$100.84 /

+7.74 (+8.31%)

07/19/22 Bernstein
Bernstein starts Datadog at Outperform with $172 price target
07/19/22 Bernstein
Datadog initiated with an Outperform at Bernstein
07/19/22 Mizuho
Datadog price target lowered to $150 from $175 at Mizuho
07/07/22 Canaccord
Datadog initiated with a Hold at Canaccord
VXRT Vaxart
$4.24 /

+0.3 (+7.62%)

05/19/22 B. Riley
Vaxart price target lowered to $6 from $7 at B. Riley
02/28/22 Piper Sandler
Piper Sandler 'impressed' by Vaxart's progress in COVID, norovirus programs
01/13/22 Piper Sandler
Vaxart COVID booster on track for first half of the year, says Piper Sandler
12/29/21 Jefferies
Vaxart assumed with a Buy at Jefferies
RVMD Revolution Medicines
$23.47 /

-1.145 (-4.65%)

06/06/22 H.C. Wainwright
Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
05/20/22 BofA
BofA starts Revolution Medicines at Neutral with $24 price target
05/20/22 BofA
Revolution Medicines initiated with a Neutral at BofA
03/01/22 Stifel
Stifel upgrades Revolution Medicines, sees good entry point after pullback
VALE Vale
$12.43 /

-0.275 (-2.17%)

07/13/22 Exane BNP Paribas
Vale downgraded to Neutral from Outperform at Exane BNP Paribas
06/29/22 Deutsche Bank
Vale price target lowered to $20 from $22 at Deutsche Bank
06/22/22 Morgan Stanley
Vale price target lowered to $16 from $22 at Morgan Stanley
06/07/22 Jefferies
Vale upgraded to Buy from Hold at Jefferies
BBWI Bath & Body Works
$31.10 /

+0.985 (+3.27%)

07/21/22 Citi
Bath & Body Works price target lowered to $42 from $54 at Citi
07/20/22 Goldman Sachs
Bath & Body Works price target lowered to $32 from $37 at Goldman Sachs
07/15/22 UBS
Bath & Body Works price target lowered to $42 from $70 at UBS
07/13/22 Evercore ISI
Evercore downgrades Bath & Body Works on reversion in consumer spending
NDAQ Nasdaq
$169.06 /

+9.67 (+6.07%)

07/21/22 Credit Suisse
Nasdaq price target raised to $202 from $189 at Credit Suisse
07/13/22 Deutsche Bank
Nasdaq price target lowered to $175 from $184 at Deutsche Bank
06/27/22 Jefferies
Nasdaq price target lowered to $174 from $182 at Jefferies
05/19/22 Deutsche Bank
Nasdaq price target lowered to $184 from $207 at Deutsche Bank
CPRI Capri Holdings
$48.18 /

+1.9 (+4.11%)

07/21/22 Credit Suisse
Capri Holdings price target lowered to $56 from $65 at Credit Suisse
07/21/22 Goldman Sachs
Capri Holdings price target lowered to $59 from $69 at Goldman Sachs
07/15/22 UBS
Capri Holdings price target lowered to $65 from $91 at UBS
07/07/22 Wells Fargo
Capri Holdings price target lowered to $70 from $85 at Wells Fargo
BMI Badger Meter
$87.24 /

+4.96 (+6.03%)

07/20/22 Stifel
Badger Meter price target lowered to $79 from $88 at Stifel
07/18/22 Northcoast
Badger Meter initiated with a Neutral at Northcoast (Friday)
04/20/22 Stifel
Badger Meter price target lowered to $88 from $93 at Stifel
01/31/22 Stifel
Badger Meter price target lowered to $93 from $103 at Stifel
NTRS Northern Trust
$97.21 /

-3.97 (-3.92%)

07/21/22 Barclays
Northern Trust price target lowered to $120 from $140 at Barclays
07/21/22 Credit Suisse
Northern Trust price target lowered to $99 from $106 at Credit Suisse
07/13/22 Deutsche Bank
Northern Trust price target lowered to $112 from $113 at Deutsche Bank
07/12/22 Citi
Northern Trust price target lowered to $100 from $125 at Citi
NEWR New Relic
$61.60 /

+9.215 (+17.59%)

07/21/22 RBC Capital
New Relic price target raised to $62 from $45 at RBC Capital
07/18/22 Truist
New Relic price target lowered to $80 from $85 at Truist
07/11/22 Morgan Stanley
New Relic downgraded to Equal Weight from Overweight at Morgan Stanley
07/07/22 Canaccord
New Relic initiated with a Buy at Canaccord
F Ford
$12.73 /

+0.14 (+1.11%)

07/21/22 Nomura
Ford upgraded to Neutral from Reduce at Nomura
07/21/22 Nomura
Ford upgraded to Neutral from Reduce at Nomura
07/18/22 Deutsche Bank
Ford price target lowered to $12 from $17 at Deutsche Bank
07/14/22 Morgan Stanley
General Motors price target lowered to $42 from $44 at Morgan Stanley
WYNN Wynn Resorts
$61.93 /

+2.35 (+3.94%)

VXRT Vaxart
$4.24 /

+0.3 (+7.62%)

VALE Vale
$12.43 /

-0.275 (-2.17%)

RYTM Rhythm Pharmaceuticals
$13.21 /

+2.63 (+24.86%)

RVMD Revolution Medicines
$23.47 /

-1.145 (-4.65%)

PYPL PayPal
$80.26 /

+2.46 (+3.16%)

NTRS Northern Trust
$97.21 /

-3.97 (-3.92%)

NFLX Netflix
$216.46 /

+14.73 (+7.30%)

NEWR New Relic
$61.60 /

+9.215 (+17.59%)

NDAQ Nasdaq
$169.06 /

+9.67 (+6.07%)

MRK Merck
$89.64 /

-2.645 (-2.87%)

MLCO Melco Resorts & Entertainment
$5.73 /

+0.44 (+8.32%)

MGM MGM Resorts
$31.30 /

+0.83 (+2.72%)

LVS Las Vegas Sands
$37.08 /

+1.54 (+4.33%)

JNPR Juniper
$28.54 /

-0.66 (-2.26%)

F Ford
$12.73 /

+0.14 (+1.11%)

DDOG Datadog
$100.84 /

+7.74 (+8.31%)

CPRI Capri Holdings
$48.18 /

+1.9 (+4.11%)

BMI Badger Meter
$87.24 /

+4.96 (+6.03%)

BKR Baker Hughes
$25.88 /

-2.32 (-8.23%)

BIIB Biogen
$207.57 /

-12.745 (-5.78%)

BBWI Bath & Body Works
$31.10 /

+0.985 (+3.27%)

BABA Alibaba
$103.97 /

-0.775 (-0.74%)

BA Boeing
$158.36 /

+2.26 (+1.45%)

ATRA Atara Biotherapeutics
$3.72 /

+0.07 (+1.92%)

ANET Arista Networks
$104.93 /

+0.135 (+0.13%)

ABT Abbott
$108.18 /

-1.34 (-1.22%)

AAPL Apple
$153.05 /

+2.13 (+1.41%)

  • 20
    Jul
WYNN Wynn Resorts
$61.93 /

+2.35 (+3.94%)

VALE Vale
$12.43 /

-0.275 (-2.17%)

PYPL PayPal
$80.26 /

+2.46 (+3.16%)

NFLX Netflix
$216.46 /

+14.73 (+7.30%)

NEWR New Relic
$61.60 /

+9.215 (+17.59%)

NDAQ Nasdaq
$169.06 /

+9.67 (+6.07%)

MRK Merck
$89.64 /

-2.645 (-2.87%)

MLCO Melco Resorts & Entertainment
$5.73 /

+0.44 (+8.32%)

MGM MGM Resorts
$31.30 /

+0.83 (+2.72%)

LVS Las Vegas Sands
$37.08 /

+1.54 (+4.33%)

F Ford
$12.73 /

+0.14 (+1.11%)

BKR Baker Hughes
$25.88 /

-2.32 (-8.23%)

BIIB Biogen
$207.57 /

-12.745 (-5.78%)

BABA Alibaba
$103.97 /

-0.775 (-0.74%)

BA Boeing
$158.36 /

+2.26 (+1.45%)

ABT Abbott
$108.18 /

-1.34 (-1.22%)

AAPL Apple
$153.05 /

+2.13 (+1.41%)

RVMD Revolution Medicines
$23.47 /

-1.145 (-4.65%)

PYPL PayPal
$80.26 /

+2.46 (+3.16%)

NFLX Netflix
$216.46 /

+14.73 (+7.30%)

NEWR New Relic
$61.60 /

+9.215 (+17.59%)

NDAQ Nasdaq
$169.06 /

+9.67 (+6.07%)

MRK Merck
$89.64 /

-2.645 (-2.87%)

MGM MGM Resorts
$31.30 /

+0.83 (+2.72%)

LVS Las Vegas Sands
$37.08 /

+1.54 (+4.33%)

JNPR Juniper
$28.54 /

-0.66 (-2.26%)

F Ford
$12.73 /

+0.14 (+1.11%)

DDOG Datadog
$100.84 /

+7.74 (+8.31%)

CPRI Capri Holdings
$48.18 /

+1.9 (+4.11%)

BMI Badger Meter
$87.24 /

+4.96 (+6.03%)

BKR Baker Hughes
$25.88 /

-2.32 (-8.23%)

BIIB Biogen
$207.57 /

-12.745 (-5.78%)

BBWI Bath & Body Works
$31.10 /

+0.985 (+3.27%)

BA Boeing
$158.36 /

+2.26 (+1.45%)

ATRA Atara Biotherapeutics
$3.72 /

+0.07 (+1.92%)

ABT Abbott
$108.18 /

-1.34 (-1.22%)

AAPL Apple
$153.05 /

+2.13 (+1.41%)

WYNN Wynn Resorts
$61.93 /

+2.35 (+3.94%)

VALE Vale
$12.43 /

-0.275 (-2.17%)

PYPL PayPal
$80.26 /

+2.46 (+3.16%)

NFLX Netflix
$216.46 /

+14.73 (+7.30%)

NEWR New Relic
$61.60 /

+9.215 (+17.59%)

MRK Merck
$89.64 /

-2.645 (-2.87%)

MLCO Melco Resorts & Entertainment
$5.73 /

+0.44 (+8.32%)

MGM MGM Resorts
$31.30 /

+0.83 (+2.72%)

LVS Las Vegas Sands
$37.08 /

+1.54 (+4.33%)

JNPR Juniper
$28.54 /

-0.66 (-2.26%)

F Ford
$12.73 /

+0.14 (+1.11%)

DDOG Datadog
$100.84 /

+7.74 (+8.31%)

CPRI Capri Holdings
$48.18 /

+1.9 (+4.11%)

BKR Baker Hughes
$25.88 /

-2.32 (-8.23%)

BIIB Biogen
$207.57 /

-12.745 (-5.78%)

BBWI Bath & Body Works
$31.10 /

+0.985 (+3.27%)

BABA Alibaba
$103.97 /

-0.775 (-0.74%)

BA Boeing
$158.36 /

+2.26 (+1.45%)

ANET Arista Networks
$104.93 /

+0.135 (+0.13%)

ABT Abbott
$108.18 /

-1.34 (-1.22%)

AAPL Apple
$153.05 /

+2.13 (+1.41%)

On The Fly
What You Missed On Wall Street This Morning » 12:27
07/20/22
07/20
12:27
07/20/22
12:27
NFLX

Netflix

$215.88 /

+14.15 (+7.01%)

, ABT

Abbott

$108.74 /

-0.78 (-0.71%)

, BKR

Baker Hughes

$25.58 /

-2.62 (-9.29%)

, BIIB

Biogen

$211.60 /

-8.715 (-3.96%)

, MRK

Merck

$90.28 /

-2.005 (-2.17%)

, BABA

Alibaba

$104.28 /

-0.46 (-0.44%)

, ATRA

Atara Biotherapeutics

$3.68 /

+0.035 (+0.96%)

, ANET

Arista Networks

$104.92 /

+0.13 (+0.12%)

, JNPR

Juniper

$28.89 /

-0.315 (-1.08%)

, PYPL

PayPal

$79.91 /

+2.11 (+2.71%)

, LVS

Las Vegas Sands

$37.03 /

+1.49 (+4.19%)

, MGM

MGM Resorts

$31.45 /

+0.985 (+3.23%)

, WYNN

Wynn Resorts

$61.74 /

+2.16 (+3.63%)

, MLCO

Melco Resorts & Entertainment

$5.68 /

+0.39 (+7.37%)

, EADSY

Airbus

$27.12 /

+0.92 (+3.51%)

, UNPRF

Uniper

$10.64 /

+1.1359 (+11.95%)

, JPM

JPMorgan

$114.62 /

+0.09 (+0.08%)

, VIVHY

Vivendi

$10.03 /

+0.22 (+2.24%)

, ORAN

Orange

$10.59 /

-0.145 (-1.35%)

, RYTM

Rhythm Pharmaceuticals

$12.09 /

+1.51 (+14.27%)

, DDOG

Datadog

$102.11 /

+9.01 (+9.68%)

, VXRT

Vaxart

$4.35 /

+0.415 (+10.55%)

, RVMD

Revolution Medicines

$22.77 /

-1.84 (-7.48%)

, VALE

Vale

$12.40 /

-0.3 (-2.36%)

, BBWI

Bath & Body Works

$29.87 /

-0.24 (-0.80%)

, NDAQ

Nasdaq

$168.76 /

+9.37 (+5.88%)

, CPRI

Capri Holdings

$47.36 /

+1.08 (+2.33%)

, BMI

Badger Meter

$85.10 /

+2.82 (+3.43%)

, NTRS

Northern Trust

$96.56 /

-4.62 (-4.57%)

Get caught up quickly on…

ShowHide Related Items >><<
WYNN Wynn Resorts
$61.74 /

+2.16 (+3.63%)

VXRT Vaxart
$4.35 /

+0.415 (+10.55%)

VIVHY Vivendi
$10.03 /

+0.22 (+2.24%)

VALE Vale
$12.40 /

-0.3 (-2.36%)

UNPRF Uniper
$10.64 /

+1.1359 (+11.95%)

RYTM Rhythm Pharmaceuticals
$12.09 /

+1.51 (+14.27%)

RVMD Revolution Medicines
$22.77 /

-1.84 (-7.48%)

PYPL PayPal
$79.91 /

+2.11 (+2.71%)

ORAN Orange
$10.59 /

-0.145 (-1.35%)

NTRS Northern Trust
$96.56 /

-4.62 (-4.57%)

NFLX Netflix
$215.88 /

+14.15 (+7.01%)

NDAQ Nasdaq
$168.76 /

+9.37 (+5.88%)

MRK Merck
$90.28 /

-2.005 (-2.17%)

MLCO Melco Resorts & Entertainment
$5.68 /

+0.39 (+7.37%)

MGM MGM Resorts
$31.45 /

+0.985 (+3.23%)

LVS Las Vegas Sands
$37.03 /

+1.49 (+4.19%)

JPM JPMorgan
$114.62 /

+0.09 (+0.08%)

JNPR Juniper
$28.89 /

-0.315 (-1.08%)

EADSY Airbus
$27.12 /

+0.92 (+3.51%)

DDOG Datadog
$102.11 /

+9.01 (+9.68%)

CPRI Capri Holdings
$47.36 /

+1.08 (+2.33%)

BMI Badger Meter
$85.10 /

+2.82 (+3.43%)

BKR Baker Hughes
$25.58 /

-2.62 (-9.29%)

BIIB Biogen
$211.60 /

-8.715 (-3.96%)

BBWI Bath & Body Works
$29.87 /

-0.24 (-0.80%)

BABA Alibaba
$104.28 /

-0.46 (-0.44%)

ATRA Atara Biotherapeutics
$3.68 /

+0.035 (+0.96%)

ABT Abbott
$108.74 /

-0.78 (-0.71%)

NFLX Netflix
$215.88 /

+14.15 (+7.01%)

07/20/22 Oppenheimer
Netflix subscriber beat unlikely to alleviate concerns, says Oppenheimer
07/20/22 Evercore ISI
Evercore says market will need to see progress from Netflix for premium multiple
07/20/22 Morgan Stanley
Netflix price target raised to $230 from $220 at Morgan Stanley
07/20/22 Wedbush
Wedbush remains bullish on Netflix following quarterly results
ABT Abbott
$108.74 /

-0.78 (-0.71%)

07/18/22 BTIG
Abbott price target lowered to $126 from $130 at BTIG
07/18/22 Stifel
Abbott price target lowered to $126 from $136 at Stifel
07/13/22 Cowen
Abbott price target lowered to $130 from $150 at Cowen
07/06/22 Wolfe Research
Wolfe starts Abbott at Underperform, says stock price 'doesn't make sense'
BKR Baker Hughes
$25.58 /

-2.62 (-9.29%)

07/13/22 Morgan Stanley
Baker Hughes price target lowered to $35 from $40 at Morgan Stanley
07/13/22 Barclays
Baker Hughes price target lowered to $46 from $47 at Barclays
06/08/22 Barclays
Baker Hughes price target raised to $47 from $40 at Barclays
04/27/22 Barclays
Baker Hughes price target raised to $40 from $31 at Barclays
BIIB Biogen
$211.60 /

-8.715 (-3.96%)

07/20/22 Piper Sandler
Biogen Q2 'surprisingly strong,' but 'rough waters' ahead, says Piper
07/20/22 Piper Sandler
Piper adjusts Ionis' Spinraza royalties estimate following Biogen report
07/19/22 Canaccord
Biogen approaching some high-risk/high-reward events, says Canaccord
07/18/22 Oppenheimer
Biogen price target raised to $230 from $225 at Oppenheimer
MRK Merck
$90.28 /

-2.005 (-2.17%)

07/18/22 UBS
Merck price target raised to $98 from $76 at UBS
07/12/22 H.C. Wainwright
H.C. Wainwright says Bellus set for 'show down' against Merck's gefapixant
07/08/22 Morgan Stanley
Merck price target raised to $88 from $87 at Morgan Stanley
07/07/22 Daiwa
Merck upgraded to Outperform from Neutral at Daiwa (yesterday)
BABA Alibaba
$104.28 /

-0.46 (-0.44%)

07/19/22 Bernstein
Alibaba upgraded to Outperform from Market Perform at Bernstein
07/11/22 Goldman Sachs
Pinduoduo grocery focus to drive sustained growth, says Goldman Sachs
07/11/22 Goldman Sachs
Alibaba price target raised to $167 from $163 at Goldman Sachs
07/06/22 Benchmark
Alibaba price target raised to $205 from $200 at Benchmark
ATRA Atara Biotherapeutics
$3.68 /

+0.035 (+0.96%)

07/20/22 Citi
Atara Biotherapeutics downgraded to Sell from Neutral at Citi
07/13/22 Canaccord
Atara Biotherapeutics price target lowered to $50 from $67 at Canaccord
07/13/22 Stifel
Stifel downgrades Atara Biotherapeutics to Hold following ATA188 analysis
07/13/22 Stifel
Atara Biotherapeutics downgraded to Hold from Buy at Stifel
ANET Arista Networks
$104.92 /

+0.13 (+0.12%)

07/20/22 BofA
Arista double downgraded to Underperform at BofA on upcoming deterioration
07/20/22 BofA
Arista Networks downgraded to Underperform from Buy at BofA
07/19/22 Needham
Needham upgrades Arista Networks to Buy, sees the company as insulated
07/19/22 Needham
Arista Networks upgraded to Buy from Hold at Needham
JNPR Juniper
$28.89 /

-0.315 (-1.08%)

07/20/22 BofA
Juniper double downgraded to Underperform at BofA on upcoming deterioration
07/20/22 BofA
Juniper downgraded to Underperform from Buy at BofA
07/14/22 JPMorgan
Juniper upgraded to Overweight from Neutral at JPMorgan
07/13/22 Evercore ISI
Juniper added to 'Tactical Outperform' list at Evercore ISI
PYPL PayPal
$79.91 /

+2.11 (+2.71%)

07/20/22 Wolfe Research
PayPal downgraded to Peer Perform from Outperform at Wolfe Research
07/20/22 Wells Fargo
PayPal price target lowered to $97 from $115 at Wells Fargo
07/20/22 JPMorgan
PayPal price target lowered to $112 from $127 at JPMorgan
07/15/22 RBC Capital
PayPal price target lowered to $92 from $110 at RBC Capital
LVS Las Vegas Sands
$37.03 /

+1.49 (+4.19%)

07/19/22 Deutsche Bank
Las Vegas Sands price target lowered to $50 from $53 at Deutsche Bank
07/06/22 JPMorgan
JPMorgan likes Las Vegas Sands risk/reward, sees 20% share upside
07/05/22 Citi
Las Vegas Sands price target lowered to $56 from $57 at Citi
06/29/22 Barclays
Barclays initiates gaming sector, says Caesars best positioned
MGM MGM Resorts
$31.45 /

+0.985 (+3.23%)

07/20/22 Truist
MGM Resorts price target lowered to $35 from $48 at Truist
07/05/22 Citi
MGM Resorts price target lowered to $56 from $59 at Citi
06/28/22 JMP Securities
MGM Resorts initiated with an Outperform at JMP Securities
05/20/22 Deutsche Bank
MGM Resorts price target lowered to $48 from $52 at Deutsche Bank
WYNN Wynn Resorts
$61.74 /

+2.16 (+3.63%)

07/05/22 Citi
Wynn Resorts price target lowered to $87.50 from $92 at Citi
06/28/22 Barclays
Wynn Resorts initiated with an Equal Weight at Barclays
05/11/22 Deutsche Bank
Wynn Resorts price target lowered to $92 from $123 at Deutsche Bank
MLCO Melco Resorts & Entertainment
$5.68 /

+0.39 (+7.37%)

07/05/22 Citi
Melco Resorts price target lowered to $11 from $12.50 at Citi
05/09/22 CICC
Melco Resorts downgraded to Market Perform from Outperform at CICC
05/06/22 CLSA
Melco Resorts & Entertainment upgraded to Buy from Outperform at CLSA
04/12/22 Citi
Citi opens '30-day positive Catalyst Watches' on Melco, Galaxy
EADSY Airbus
$27.12 /

+0.92 (+3.51%)

07/13/22 Kepler Cheuvreux
Airbus upgraded to Buy from Hold at Kepler Cheuvreux
06/27/22 Morgan Stanley
Airbus price target lowered to EUR 135 from EUR 137 at Morgan Stanley
06/16/22 Citi
Boeing upgraded to Buy from Neutral at Citi
06/15/22 Berenberg
Airbus price target raised to EUR 150 from EUR 140 at Berenberg
UNPRF Uniper
$10.64 /

+1.1359 (+11.95%)

07/14/22 Goldman Sachs
Uniper upgraded to Neutral from Sell at Goldman Sachs
04/28/22 UBS
Uniper price target lowered to EUR 25 from EUR 39 at UBS
04/08/22 JPMorgan
Uniper price target lowered to EUR 32 from EUR 35.50 at JPMorgan
04/04/22 RBC Capital
Uniper price target lowered to EUR 30 from EUR 40 at RBC Capital
JPM JPMorgan
$114.62 /

+0.09 (+0.08%)

07/18/22 Berenberg
JPMorgan upgraded to Hold from Sell at Berenberg
07/15/22 RBC Capital
JPMorgan price target lowered to $130 from $155 at RBC Capital
07/15/22 Evercore ISI
JPMorgan price target lowered to $125 from $135 at Evercore ISI
07/15/22 Oppenheimer
JPMorgan price target lowered to $153 from $154 at Oppenheimer
VIVHY Vivendi
$10.03 /

+0.22 (+2.24%)

04/26/22 Credit Suisse
Vivendi price target raised to EUR 13.10 from EUR 13 at Credit Suisse
04/25/22 JPMorgan
Vivendi price target raised to EUR 13.60 from EUR 13.30 at JPMorgan
04/11/22 Credit Suisse
Vivendi price target raised to EUR 13.10 from EUR 13 at Credit Suisse
03/16/22 Deutsche Bank
Vivendi price target lowered to EUR 14 from EUR 15 at Deutsche Bank
ORAN Orange
$10.59 /

-0.145 (-1.35%)

07/12/22 Morgan Stanley
Orange price target raised to EUR 13 from EUR 11 at Morgan Stanley
06/22/22 Barclays
Orange upgraded to Equal Weight from Underweight at Barclays
06/13/22 Bernstein
Orange upgraded to Outperform from Market Perform at Bernstein
04/27/22 Barclays
Orange price target raised to EUR 9.50 from EUR 9 at Barclays
RYTM Rhythm Pharmaceuticals
$12.09 /

+1.51 (+14.27%)

07/20/22 Stifel
Rhythm Pharmaceuticals price target raised to $37 from $25 at Stifel
07/13/22 Ladenburg
Rhythm Pharmaceuticals price target raised to $23 from $15 at Ladenburg
07/12/22 Goldman Sachs
Rhythm Pharmaceuticals price target raised to $6 from $4 at Goldman Sachs
06/17/22 Needham
Rhythm Pharmaceuticals price target lowered to $25 from $40 at Needham
DDOG Datadog
$102.11 /

+9.01 (+9.68%)

07/19/22 Bernstein
Bernstein starts Datadog at Outperform with $172 price target
07/19/22 Bernstein
Datadog initiated with an Outperform at Bernstein
07/19/22 Mizuho
Datadog price target lowered to $150 from $175 at Mizuho
07/07/22 Canaccord
Datadog initiated with a Hold at Canaccord
VXRT Vaxart
$4.35 /

+0.415 (+10.55%)

05/19/22 B. Riley
Vaxart price target lowered to $6 from $7 at B. Riley
02/28/22 Piper Sandler
Piper Sandler 'impressed' by Vaxart's progress in COVID, norovirus programs
01/13/22 Piper Sandler
Vaxart COVID booster on track for first half of the year, says Piper Sandler
12/29/21 Jefferies
Vaxart assumed with a Buy at Jefferies
RVMD Revolution Medicines
$22.77 /

-1.84 (-7.48%)

06/06/22 H.C. Wainwright
Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
05/20/22 BofA
BofA starts Revolution Medicines at Neutral with $24 price target
05/20/22 BofA
Revolution Medicines initiated with a Neutral at BofA
03/01/22 Stifel
Stifel upgrades Revolution Medicines, sees good entry point after pullback
VALE Vale
$12.40 /

-0.3 (-2.36%)

07/13/22 Exane BNP Paribas
Vale downgraded to Neutral from Outperform at Exane BNP Paribas
06/29/22 Deutsche Bank
Vale price target lowered to $20 from $22 at Deutsche Bank
06/22/22 Morgan Stanley
Vale price target lowered to $16 from $22 at Morgan Stanley
06/07/22 Jefferies
Vale upgraded to Buy from Hold at Jefferies
BBWI Bath & Body Works
$29.87 /

-0.24 (-0.80%)

07/15/22 UBS
Bath & Body Works price target lowered to $42 from $70 at UBS
07/13/22 Evercore ISI
Evercore downgrades Bath & Body Works on reversion in consumer spending
07/13/22 Evercore ISI
Bath & Body Works downgraded to In Line from Outperform at Evercore ISI
07/12/22 Raymond James
Bath & Body Works initiated with a Strong Buy at Raymond James
NDAQ Nasdaq
$168.76 /

+9.37 (+5.88%)

07/13/22 Deutsche Bank
Nasdaq price target lowered to $175 from $184 at Deutsche Bank
06/27/22 Jefferies
Nasdaq price target lowered to $174 from $182 at Jefferies
05/19/22 Deutsche Bank
Nasdaq price target lowered to $184 from $207 at Deutsche Bank
04/21/22 Deutsche Bank
Nasdaq price target lowered to $207 from $210 at Deutsche Bank
CPRI Capri Holdings
$47.36 /

+1.08 (+2.33%)

07/15/22 UBS
Capri Holdings price target lowered to $65 from $91 at UBS
07/07/22 Wells Fargo
Capri Holdings price target lowered to $70 from $85 at Wells Fargo
06/15/22 Jefferies
Capri Holdings transferred with a Buy at Jefferies
06/06/22 UBS
Capri Holdings price target lowered to $91 from $107 at UBS
BMI Badger Meter
$85.10 /

+2.82 (+3.43%)

07/20/22 Stifel
Badger Meter price target lowered to $79 from $88 at Stifel
07/18/22 Northcoast
Badger Meter initiated with a Neutral at Northcoast (Friday)
04/20/22 Stifel
Badger Meter price target lowered to $88 from $93 at Stifel
01/31/22 Stifel
Badger Meter price target lowered to $93 from $103 at Stifel
NTRS Northern Trust
$96.56 /

-4.62 (-4.57%)

07/13/22 Deutsche Bank
Northern Trust price target lowered to $112 from $113 at Deutsche Bank
07/12/22 Citi
Northern Trust price target lowered to $100 from $125 at Citi
07/11/22 JPMorgan
Northern Trust price target lowered to $107.50 from $115 at JPMorgan
07/01/22 RBC Capital
Northern Trust price target lowered to $110 from $133 at RBC Capital
WYNN Wynn Resorts
$61.74 /

+2.16 (+3.63%)

VXRT Vaxart
$4.35 /

+0.415 (+10.55%)

VALE Vale
$12.40 /

-0.3 (-2.36%)

UNPRF Uniper
$10.64 /

+1.1359 (+11.95%)

RYTM Rhythm Pharmaceuticals
$12.09 /

+1.51 (+14.27%)

RVMD Revolution Medicines
$22.77 /

-1.84 (-7.48%)

PYPL PayPal
$79.91 /

+2.11 (+2.71%)

NTRS Northern Trust
$96.56 /

-4.62 (-4.57%)

NFLX Netflix
$215.88 /

+14.15 (+7.01%)

NDAQ Nasdaq
$168.76 /

+9.37 (+5.88%)

MRK Merck
$90.28 /

-2.005 (-2.17%)

MLCO Melco Resorts & Entertainment
$5.68 /

+0.39 (+7.37%)

MGM MGM Resorts
$31.45 /

+0.985 (+3.23%)

LVS Las Vegas Sands
$37.03 /

+1.49 (+4.19%)

JPM JPMorgan
$114.62 /

+0.09 (+0.08%)

JNPR Juniper
$28.89 /

-0.315 (-1.08%)

EADSY Airbus
$27.12 /

+0.92 (+3.51%)

DDOG Datadog
$102.11 /

+9.01 (+9.68%)

CPRI Capri Holdings
$47.36 /

+1.08 (+2.33%)

BMI Badger Meter
$85.10 /

+2.82 (+3.43%)

BKR Baker Hughes
$25.58 /

-2.62 (-9.29%)

BIIB Biogen
$211.60 /

-8.715 (-3.96%)

BBWI Bath & Body Works
$29.87 /

-0.24 (-0.80%)

BABA Alibaba
$104.28 /

-0.46 (-0.44%)

ATRA Atara Biotherapeutics
$3.68 /

+0.035 (+0.96%)

ANET Arista Networks
$104.92 /

+0.13 (+0.12%)

ABT Abbott
$108.74 /

-0.78 (-0.71%)

  • 20
    Jul
WYNN Wynn Resorts
$61.74 /

+2.16 (+3.63%)

VIVHY Vivendi
$10.03 /

+0.22 (+2.24%)

VALE Vale
$12.40 /

-0.3 (-2.36%)

UNPRF Uniper
$10.64 /

+1.1359 (+11.95%)

PYPL PayPal
$79.91 /

+2.11 (+2.71%)

NFLX Netflix
$215.88 /

+14.15 (+7.01%)

NDAQ Nasdaq
$168.76 /

+9.37 (+5.88%)

MRK Merck
$90.28 /

-2.005 (-2.17%)

MLCO Melco Resorts & Entertainment
$5.68 /

+0.39 (+7.37%)

MGM MGM Resorts
$31.45 /

+0.985 (+3.23%)

LVS Las Vegas Sands
$37.03 /

+1.49 (+4.19%)

JPM JPMorgan
$114.62 /

+0.09 (+0.08%)

EADSY Airbus
$27.12 /

+0.92 (+3.51%)

BKR Baker Hughes
$25.58 /

-2.62 (-9.29%)

BIIB Biogen
$211.60 /

-8.715 (-3.96%)

BABA Alibaba
$104.28 /

-0.46 (-0.44%)

ABT Abbott
$108.74 /

-0.78 (-0.71%)

VIVHY Vivendi
$10.03 /

+0.22 (+2.24%)

UNPRF Uniper
$10.64 /

+1.1359 (+11.95%)

RYTM Rhythm Pharmaceuticals
$12.09 /

+1.51 (+14.27%)

RVMD Revolution Medicines
$22.77 /

-1.84 (-7.48%)

PYPL PayPal
$79.91 /

+2.11 (+2.71%)

NFLX Netflix
$215.88 /

+14.15 (+7.01%)

NDAQ Nasdaq
$168.76 /

+9.37 (+5.88%)

MRK Merck
$90.28 /

-2.005 (-2.17%)

MGM MGM Resorts
$31.45 /

+0.985 (+3.23%)

LVS Las Vegas Sands
$37.03 /

+1.49 (+4.19%)

JPM JPMorgan
$114.62 /

+0.09 (+0.08%)

JNPR Juniper
$28.89 /

-0.315 (-1.08%)

EADSY Airbus
$27.12 /

+0.92 (+3.51%)

DDOG Datadog
$102.11 /

+9.01 (+9.68%)

CPRI Capri Holdings
$47.36 /

+1.08 (+2.33%)

BMI Badger Meter
$85.10 /

+2.82 (+3.43%)

BKR Baker Hughes
$25.58 /

-2.62 (-9.29%)

BIIB Biogen
$211.60 /

-8.715 (-3.96%)

BBWI Bath & Body Works
$29.87 /

-0.24 (-0.80%)

BABA Alibaba
$104.28 /

-0.46 (-0.44%)

ATRA Atara Biotherapeutics
$3.68 /

+0.035 (+0.96%)

ANET Arista Networks
$104.92 /

+0.13 (+0.12%)

ABT Abbott
$108.74 /

-0.78 (-0.71%)

WYNN Wynn Resorts
$61.74 /

+2.16 (+3.63%)

VALE Vale
$12.40 /

-0.3 (-2.36%)

PYPL PayPal
$79.91 /

+2.11 (+2.71%)

NFLX Netflix
$215.88 /

+14.15 (+7.01%)

MRK Merck
$90.28 /

-2.005 (-2.17%)

MLCO Melco Resorts & Entertainment
$5.68 /

+0.39 (+7.37%)

MGM MGM Resorts
$31.45 /

+0.985 (+3.23%)

LVS Las Vegas Sands
$37.03 /

+1.49 (+4.19%)

JPM JPMorgan
$114.62 /

+0.09 (+0.08%)

JNPR Juniper
$28.89 /

-0.315 (-1.08%)

DDOG Datadog
$102.11 /

+9.01 (+9.68%)

CPRI Capri Holdings
$47.36 /

+1.08 (+2.33%)

BKR Baker Hughes
$25.58 /

-2.62 (-9.29%)

BIIB Biogen
$211.60 /

-8.715 (-3.96%)

BBWI Bath & Body Works
$29.87 /

-0.24 (-0.80%)

BABA Alibaba
$104.28 /

-0.46 (-0.44%)

ANET Arista Networks
$104.92 /

+0.13 (+0.12%)

ABT Abbott
$108.74 /

-0.78 (-0.71%)

Hot Stocks
Vaxart reports phase 1 clinical data on its oral tablet COVID-19 vaccine » 08:32
07/20/22
07/20
08:32
07/20/22
08:32
VXRT

Vaxart

$3.94 /

+0.15 (+3.96%)

Vaxart reported…

Vaxart reported additional phase 1 clinical data published on medRixv.org, indicating that its Spike/Nucleocapsid oral tablet COVID-19 vaccine induced long-lasting mucosal IgA antibodies against SARS-CoV-2 the virus that causes COVID-19, and all tested coronaviruses. The neutralizing activity of these IgA antibodies in responders was higher than that measured in convalescent samples. "One of the most important challenges with current COVID-19 vaccine strategies is that injected vaccines stimulate robust serum antibody responses against the Wuhan strain of SARS-CoV-2, but these responses quickly decline, and they are not as effective against the currently circulating viral variants. This has resulted in breakthrough infections in many people who have received injected vaccines," said the article's lead author, Dr. Sean Tucker, Vaxart's SVP and Chief Scientific Officer. "Our clinical study results showed that our vaccine candidate stimulates broadly cross-reactive mucosal IgA responses that persist for at least 6 months in most responders, and up to a year in a subset of them following just a single dose. Two key observations in this study were that vaccination induced a similar mucosal IgA response as seen in convalescent subjects, and that the vaccinated subjects appeared to have better neutralizing antibody potential in the mucosa than infected subjects. We are excited to explore these aspects in depth in future studies," he said.

ShowHide Related Items >><<
VXRT Vaxart
$3.94 /

+0.15 (+3.96%)

VXRT Vaxart
$3.94 /

+0.15 (+3.96%)

05/19/22 B. Riley
Vaxart price target lowered to $6 from $7 at B. Riley
02/28/22 Piper Sandler
Piper Sandler 'impressed' by Vaxart's progress in COVID, norovirus programs
01/13/22 Piper Sandler
Vaxart COVID booster on track for first half of the year, says Piper Sandler
12/29/21 Jefferies
Vaxart assumed with a Buy at Jefferies
VXRT Vaxart
$3.94 /

+0.15 (+3.96%)

Over a month ago
Hot Stocks
Vaxart provides update on proxy voting, urges stockholders to vote » 09:04
07/01/22
07/01
09:04
07/01/22
09:04
VXRT

Vaxart

$3.49 /

-0.05 (-1.41%)

Vaxart urges its…

Vaxart urges its stockholders of record on April 11, 2022, to vote on its proxy if they have not yet done so. The Company urges a yes vote on all Proxy Proposals, including Proxy Proposal #2. Andrei Floroiu, Vaxart Chief Executive Officer said, "Proposal #2 will give us the flexibility to continue to be thoughtful and opportunistic in raising capital so we can fund the business, maintain a strong balance sheet as we progress our programs, make us a more attractive partner to governments and put us in a stronger competitive position. I join our Board of Directors in stating that we believe the approval of Proposal #2 would allow us the best options to raise the capital needed to accelerate our promising pipeline."

ShowHide Related Items >><<
VXRT Vaxart
$3.49 /

-0.05 (-1.41%)

VXRT Vaxart
$3.49 /

-0.05 (-1.41%)

05/19/22 B. Riley
Vaxart price target lowered to $6 from $7 at B. Riley
02/28/22 Piper Sandler
Piper Sandler 'impressed' by Vaxart's progress in COVID, norovirus programs
01/13/22 Piper Sandler
Vaxart COVID booster on track for first half of the year, says Piper Sandler
12/29/21 Jefferies
Vaxart assumed with a Buy at Jefferies
VXRT Vaxart
$3.49 /

-0.05 (-1.41%)

Hot Stocks
Vaxart, hVIVO sign agreement to develop first human omicron challenge model » 08:04
06/30/22
06/30
08:04
06/30/22
08:04
VXRT

Vaxart

$3.54 /

+0.045 (+1.29%)

Vaxart VXRT announced an…

Vaxart VXRT announced an agreement with hVIVO Services Limited, a subsidiary of Open Orphan under which hVIVO will conduct a characterization study and, if successful, develop a human challenge model based on the Omicron variant of SARS-CoV-2 with the intent to conduct a subsequent Phase II Human Challenge Trial, HCT, of Vaxart's oral COVID-19 vaccine pill candidate. "We are excited at the prospect of testing our vaccine candidates in a human Omicron challenge model particularly given the preclinical data we reported earlier this month that showed two of our COVID-19 vaccine constructs could protect against the Omicron BA.1 variant. A human challenge study of our oral COVID-19 vaccine pill candidate against the Omicron variant of SARS-CoV-2 is the most rapid and direct way to assess the efficacy of this candidate against a highly prevalent viral strain," said Dr. James Cummings, Vaxart's Chief Medical Officer. Following manufacture of the challenge virus, hVIVO will conduct a characterization study to establish a dose of the Omicron challenge virus that will cause a safe and reliable infection in healthy volunteers. The study will enroll healthy male and female volunteers who have previously been vaccinated against or infected with SARS-CoV-2, with no known risk factors for severe COVID-19 and low levels of serum neutralizing antibodies. Subject to the successful completion of the characterization study and receipt of relevant regulatory approvals, the Omicron human challenge trial is expected to begin in 2023.

ShowHide Related Items >><<
VXRT Vaxart
$3.54 /

+0.045 (+1.29%)

VXRT Vaxart
$3.54 /

+0.045 (+1.29%)

05/19/22 B. Riley
Vaxart price target lowered to $6 from $7 at B. Riley
02/28/22 Piper Sandler
Piper Sandler 'impressed' by Vaxart's progress in COVID, norovirus programs
01/13/22 Piper Sandler
Vaxart COVID booster on track for first half of the year, says Piper Sandler
12/29/21 Jefferies
Vaxart assumed with a Buy at Jefferies
VXRT Vaxart
$3.54 /

+0.045 (+1.29%)

Hot Stocks
Vaxart announces adjournment of Annual Meeting of Stockholders » 09:13
06/08/22
06/08
09:13
06/08/22
09:13
VXRT

Vaxart

$3.74 /

+0.305 (+8.89%)

Vaxart announced that its…

Vaxart announced that its 2022 annual meeting of stockholders has been adjourned to Wednesday, July 6, 2022 at 9:30 a.m. Pacific Time with respect to all proposals described in Vaxart's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 28, 2022. The reconvened Annual Meeting will be held at the offices of Vaxart, Inc. located at 170 Harbor Way, Suite 300, South San Francisco, California 94080. During the adjournment, Vaxart continues to solicit votes from its stockholders with respect to all proposals set forth in the Proxy Statement. At the time the Annual Meeting was adjourned, proxies had been submitted by stockholders representing approximately 58.22% of the shares of Vaxart's common stock outstanding and entitled to vote, which constituted a quorum. At the time of the Annual Meeting votes were sufficient to approve: Proposal 1 - Election of Directors and the election of all of the board of directors' seven nominees for director, Proposal 3 - Approval of Amendment and Restatement of the 2019 Equity Incentive Plan, Proposal 4 - Approval of the 2022 Employee Stock Purchase Plan, Proposal 5 - Ratification of Selection of Independent Registered Public Accounting Firm, Proposal 6 - Approval of the Compensation of the Vaxart's Named Executive Officers. At the time of the Annual Meeting votes were not sufficient to approve Proposal 2 - Adoption of an Amendment to Vaxart's Restated Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock, which requires approval by the holders of a majority of the outstanding shares of common stock of Vaxart. At the time of the Annual Meeting, approximately 73.3% of the votes cast on Proposal 2 were voted in favor of its approval, which constitutes approximately 42.1% of the outstanding shares in favor. Proxies previously submitted with respect to the Annual Meeting will be voted on all proposals at the adjourned Annual Meeting unless properly revoked in accordance with the procedures described in the Proxy Statement, and stockholders who have previously submitted a proxy or otherwise voted need not take any action. The Board of Directors of Vaxart believes that the approval of Proposal 2 regarding the Authorized Shares Increase is in the best interests of the stockholders of Vaxart. In the event the Authorized Shares Increase is not approved, there may not be sufficient shares of common stock for Vaxart to increase the number of authorized shares of common stock to give Vaxart greater flexibility in considering and planning for future corporate needs, including, but not limited to: raising additional capital, which is needed to fund ongoing clinical and nonclinical research programs; considering potential strategic transactions, including mergers, acquisitions, and business combinations; funding operations; issuing shares; making long-term equity incentive awards under Vaxart's equity compensation plans; attracting and retaining key employees, consultants, advisors, executive officers, and directors; and other general corporate purposes.

ShowHide Related Items >><<
VXRT Vaxart
$3.74 /

+0.305 (+8.89%)

VXRT Vaxart
$3.74 /

+0.305 (+8.89%)

05/19/22 B. Riley
Vaxart price target lowered to $6 from $7 at B. Riley
02/28/22 Piper Sandler
Piper Sandler 'impressed' by Vaxart's progress in COVID, norovirus programs
01/13/22 Piper Sandler
Vaxart COVID booster on track for first half of the year, says Piper Sandler
12/29/21 Jefferies
Vaxart assumed with a Buy at Jefferies
VXRT Vaxart
$3.74 /

+0.305 (+8.89%)

VXRT Vaxart
$3.74 /

+0.305 (+8.89%)

Hot Stocks
Vaxart reports preliminary preclinical data on two COVID-19 vaccine candidates » 08:08
06/03/22
06/03
08:08
06/03/22
08:08
VXRT

Vaxart

$3.53 /

+0.07 (+2.03%)

Vaxart reported positive…

Vaxart reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike protein for Wuhan or S protein for Omicron protected hamsters when challenged with the Omicron BA.1 variant. The data reported are from a study in which the S-only Wuhan and Omicron vaccine candidates were compared in a hamster challenge model. Animals were immunized mucosally on days zero and 28 and challenged on day 56 with an Omicron variant of SARS-CoV-2; Both vaccines produced antibody responses to the S protein of Omicron, with the Omicron candidate slightly better at making serum IgG antibodies to the matched protein; Weight loss, lung viral titers, and viral shedding were reduced in animals receiving either vaccine candidate compared to unvaccinated animals.

ShowHide Related Items >><<
VXRT Vaxart
$3.53 /

+0.07 (+2.03%)

VXRT Vaxart
$3.53 /

+0.07 (+2.03%)

05/19/22 B. Riley
Vaxart price target lowered to $6 from $7 at B. Riley
02/28/22 Piper Sandler
Piper Sandler 'impressed' by Vaxart's progress in COVID, norovirus programs
01/13/22 Piper Sandler
Vaxart COVID booster on track for first half of the year, says Piper Sandler
12/29/21 Jefferies
Vaxart assumed with a Buy at Jefferies
VXRT Vaxart
$3.53 /

+0.07 (+2.03%)

VXRT Vaxart
$3.53 /

+0.07 (+2.03%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.